2018

The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in *Mycobacterium tuberculosis* complex: technical guide

World Health Organization

FIND
Because diagnosis matters
WHO collaborating centre for the evaluation of new diagnostic technologies

The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in *Mycobacterium tuberculosis* complex: technical guide

World Health Organization

FIND
Because diagnosis matters
WHO collaborating centre for the evaluation of new diagnostic technologies

WHO/CDS/TB/2018.19

Suggested citation. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva: World Health Organization; 2018 (WHO/CDS/TB/2018.19). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Printed in Spain

Contents

Acknowledgements

The development of this document was led by FIND with contributions from Sophia Georghiou, Timothy Rodwell, Rebecca Colman, Paolo Miotto, Arnold Bainomugisa, Andrea Cabibbe, Anita Suresh and Claudia Denkinger. Technical input and review was provided by Christopher Gilpin, Alexei Korobitsyn, Anna Dean, Karin Weyer and Matteo Zignol (WHO Global TB Programme).

External Review Group

Heidi Albert (FIND South Africa, Cape Town, South Africa); Heather Alexander (Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, USA); Martina Casenghi (Elizabeth Glaiser Pediatric AIDS Foundation, Geneva, Switzerland); Chris Coulter (Queensland Department of Health, Brisbane, Australia); Daniela Cirillo (San Raffaele Scientific Institute, Milan, Italy); Masoud Dara (WHO Regional Office For Europe, Copenhagen, Denmark); Soudeh Ehsani (WHO Regional Office For Europe, Copenhagen, Denmark); Lucilaine Ferrazoli (TB and Mycobacteriology Laboratory Adolfo Lutz Institute, Sao Paulo, Brazil); Bernard Fourie (University of Pretoria, South Africa); Levan Gagnidze (International Organization for Migration, Bangkok, Thailand); Petra de Haas (KNCV Tuberculosis Foundation , The Hague, The Netherlands); Zahra Hasan (The Aga Khan University, Karachi, Pakistan); Rumina Hasan (The Aga Khan University, Karachi, Pakistan Sven Hoffner (Karolinska Institute, Stockholm, Sweden); Nguyen Van Hung (National TB Reference Laboratory, National Lung Hospital, Hanoi, Viet Nam); Nazir Ismail (National Institute of Communicable Diseases, Johannesburg, South Africa); Connor Meehan (Institute of Tropical Medicine, Antwerp, Belgium); Igor Mokrousov (St Petersburg Pasteur Institute, St. Petersburg, Russian Federation); Moses Joloba (National Reference Laboratory of the National TB and Leprosy Programme, Kampala, Uganda); Lindiwe Mvusi (National Department of Health, South Africa); Alaine Umubyeyi Nyaruhirira (Management Science for Health, Gauteng, South Africa); Daniel Orozco (Partners In Health, Boston, USA); Jamie Posey (Mycobacteriology Laboratory Branch, Centers for Disease Control and Prevention, Atlanta USA); Leen Rigouts (Institute of Tropical Medicine, Antwerp, Belgium); Camilla Rodrigues (P.D. Hinduja Hospital & Medical Research Centre, India); Marco Schito (Critical Path Institute, Tucson, USA); Kaiser Shen (US Agency for International Development (USAID), Washington, USA); Thomas Shinnick (Independent consultant, USA); Alena Skrahina (Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus); Khairunisa Suleiman (Médecins Sans Frontières Access Campaign, Geneva, Switzerland), Nairobi, Kenya); Elisa Tagliani (San Raffaele Scientific Institute, Milan, Italy); Sabira Tahseen (National TB Reference Laboratory, National Institute of Health, Islamabad, Pakistan); Maria Alice Telles (Tuberculosis Laboratory Independent Consultant for PAHO, Sao Paulo, Brazil); Francis Varaine (Médecins Sans Frontières, France); William Wells (US Agency for International Development (USAID), Washington, USA).

Target Product Profile (TPP): Detection of resistance associated mutations in *Mycobacterium tuberculosis* complex utilizing Next Generation Sequencing

The TPP was drafted by FIND (Rebecca Colman, Timothy Rodwell, David Dolinger and Claudia Denkinger) with comments incorporated from CPTR assay development working group, CPTR surveillance working group, New Diagnostic Working Group, and a web-based survey sent out to GLI listserve and GHDonline. The final consensus TPP is presented in Appendix 3.

Acknowledgement of financial support

FIND provided funding for performing the systematic review and preparing the draft guide. Funding from the United States Agency for International Development through USAID-WHO Consolidated Grant No. GHA-G-00-09-00003 / US2014-741 is also gratefully acknowledged.

Abbreviations

AMK	amikacin
BDQ	bedaquiline
CAP	capreomycin
CB	clinical breakpoint
CC	critical concentration
CFZ	clofazimine
CPTR	Critical Path to TB Drug Regimens
DCS	D-cycloserine
DLM	delamanid
DR-TB	drug-resistant tuberculosis
DST	drug susceptibility testing
FQs	fluoroquinolones
GFX	gatifloxacin
INH	isoniazid
IT	information technology
KAN	kanamycin
LFX	levofloxacin
LJ	Löwenstein-Jensen
LR	Likelihood ratio
LZD	linezolid
MDR-TB	multidrug-resistant tuberculosis
MFX	moxifloxacin